Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obagi Medical Products, Inc.    

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Valeant to buy Obagi Medical for about $344 million

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 02:12pm CET

Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology business.

The offer price of $19.75 per share represents a 28 percent premium to Obagi's Tuesday closing price.

Obagi's board has unanimously approved the deal, Valeant said in a statement on Wednesday.

The company said it expects the transaction to close in the first half of 2013 and immediately add to its cash earnings per share.

The deal is expected to save at least $40 million in annual costs within six months of closing.

Valeant, Canada's largest publicly traded drugmaker, has been building up its dermatology and aesthetics portfolio in the United States over the past one year.

It has acquired about a dozen smaller companies over the past year, including the $2.6 billion purchase of U.S.-based Medicis Pharmaceuticals Corp in December that added Botox competitor Dysport and other skin care drugs to its products.

Chief Executive J. Michael Pearson told Reuters in February that Valeant was in talks for more acquisitions and was also open to discuss a potential "merger of equals."

Obagi, which makes topical aesthetic products, had a revenue of about $120 million in 2012.

"Obagi is a leader in the physician dispensed market and enjoys a strong brand perception among physicians. The addition of their products will ... expand our market presence with dermatologists and plastic surgeons," Pearson said.

Obagi shares were trading up near the offer price at $19.71 in premarket trading.

(Reporting by Esha Dey, Bhaswati Mukhopadhyay and Vrinda Manocha in Bangalore; Editing by Roshni Menon and Joyjeet Das)

share with twitter share with LinkedIn share with facebook
share via e-mail
2013 Exclusive - Activist investor Voce pushes ConMed to sell
2013 OBAGI MEDICAL PRODUCTS, INC. : Valeant Pharmaceuticals International, Inc. Anno..
2013 OBAGI MEDICAL PRODUCTS, INC. : Valeant Pharmaceuticals Announces Receipt Of Anti..
2013 Merz Pharma Withdraws Offer for Obagi Medical After Valeant's Sweetened Bid
2013 Valeant to Launch Own Version of Generic Zovirax in Response to Mylan's
2013 Valeant sweetens bid for Obagi Medical
2013 U.S. HOT STOCK FUTURES : Hot stocks to watch
2013 Valeant Boosts Price for Obagi to $420 Million, Besting Merz Offer
2013 OBAGI MEDICAL PRODUCTS, INC. : and Valeant Pharmaceuticals, Inc. Agree on an Inc..
2013 OBAGI MEDICAL PRODUCTS, INC. : Valeant Pharmaceuticals And Obagi Medical Product..
More news
Income Statement Evolution